TY - JOUR
T1 - Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model for Heart Development and Congenital Heart Disease
AU - Doyle, Michelle J.
AU - Lohr, Jamie L.
AU - Chapman, Christopher S.
AU - Koyano-Nakagawa, Naoko
AU - Garry, Mary G.
AU - Garry, Daniel J.
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
PY - 2015/10/10
Y1 - 2015/10/10
N2 - Congenital heart disease (CHD) remains a significant health problem, with a growing population of survivors with chronic disease. Despite intense efforts to understand the genetic basis of CHD in humans, the etiology of most CHD is unknown. Furthermore, new models of CHD are required to better understand the development of CHD and to explore novel therapies for this patient population. In this review, we highlight the role that human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes can serve to enhance our understanding of the development, pathophysiology and potential therapeutic targets for CHD. We highlight the use of hiPSC-derived cardiomyocytes to model gene regulatory interactions, cell-cell interactions and tissue interactions contributing to CHD. We further emphasize the importance of using hiPSC-derived cardiomyocytes as personalized research models. The use of hiPSCs presents an unprecedented opportunity to generate disease-specific cellular models, investigate the underlying molecular mechanisms of disease and uncover new therapeutic targets for CHD.
AB - Congenital heart disease (CHD) remains a significant health problem, with a growing population of survivors with chronic disease. Despite intense efforts to understand the genetic basis of CHD in humans, the etiology of most CHD is unknown. Furthermore, new models of CHD are required to better understand the development of CHD and to explore novel therapies for this patient population. In this review, we highlight the role that human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes can serve to enhance our understanding of the development, pathophysiology and potential therapeutic targets for CHD. We highlight the use of hiPSC-derived cardiomyocytes to model gene regulatory interactions, cell-cell interactions and tissue interactions contributing to CHD. We further emphasize the importance of using hiPSC-derived cardiomyocytes as personalized research models. The use of hiPSCs presents an unprecedented opportunity to generate disease-specific cellular models, investigate the underlying molecular mechanisms of disease and uncover new therapeutic targets for CHD.
KW - Cardiomyocytes
KW - Congenital heart disease
KW - Heart development
KW - Human induced pluripotent stem cells
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=84941185483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941185483&partnerID=8YFLogxK
U2 - 10.1007/s12015-015-9596-6
DO - 10.1007/s12015-015-9596-6
M3 - Article
C2 - 26085192
AN - SCOPUS:84941185483
SN - 1550-8943
VL - 11
SP - 710
EP - 727
JO - Stem Cell Reviews and Reports
JF - Stem Cell Reviews and Reports
IS - 5
ER -
